Akoustis Technologies Inc. logo

Akoustis Technologies Inc. (AKTS)

Market Closed
27 Jul, 20:00
NASDAQ (CM) NASDAQ (CM)
$
24. 21
+0.32
+1.3395%
$
1.32B Market Cap
- P/E Ratio
- Div Yield
257,097 Volume
-0.73 Eps
$ 23.89
Previous Close
Analysts:
Add Transaction
Day Range
24.16 25.2
Year Range
14.72 34.19
Want to track AKTS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

AKTS closed today higher at $24.21, an increase of 1.3395% from yesterday's close, completing a monthly increase of 17.5814% or $3.62. Over the past 12 months, AKTS stock lost -10.3333%.
AKTS is not paying dividends to its shareholders.
The last earnings report, released on Nov 12, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Akoustis Technologies Inc. has completed 1 stock splits, with the recent split occurring on Apr 24, 2015.
The company's stock is traded on one exchange.

AKTS Chart

People also search for

Karooooo Ltd.
$ 63.49
+0.2368%
BVC
BitVentures Limited
$ 11
+5.0621%
NN
NextNav Inc.
$ 12.68
+1.9293%
Biolife Solutions Inc.
$ 29.79
-0.6338%
SkyWater Technology, Inc.
$ 31.59
+3.1679%
Aktis Oncology: Mini-Proteins With A Targeted Punch

Aktis Oncology: Mini-Proteins With A Targeted Punch

Aktis Oncology trades at a $1.1B market cap with $540M cash, pricing its pipeline and Eli Lilly collaboration at $560M. The investment thesis hinges on the mini-protein platform targeting Nectin-4, with lead asset AKY-1189's Phase Ib data expected Q1 2027 as a binary catalyst. My conservative base case yields $12/share equity value, well below the ~$20 market price, implying patient expansion is already priced in.

Seekingalpha | 1 month ago
Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting

Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting

Aktis Oncology is initiated with a "Buy" rating, driven by its innovative miniprotein radioconjugates targeting Nectin-4 and B7-H3 solid tumors. The company expects key catalysts: AKY-1189 phase 1b Part 1 data in Q1 2027 and AKY-2519 ASCO poster presentations and phase 1b initiation in mid-2026. The company's approach aims to expand the radiopharmaceutical market beyond PSMA and SSTR2, leveraging alpha-emitting actinium-225 for broader tumor targeting potential.

Seekingalpha | 3 months ago
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know

Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know

The mean of analysts' price targets for Aktis (AKTS) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks | 3 months ago

Akoustis Technologies Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
George Soros
George Soros Soros Fund Management LLC
100,000 $1.79M $2.46M $668,000 37.34%
John H. Burbank III
John H. Burbank III Passport Capital LLC
996,351 $17.82M $24.45M $6.63M 37.17%
Joseph Castro
Joseph Castro Nuveen LLC
24,468 $437,733 $586,253.28 $148,520.28 33.93%
Ellen York
Ellen York T. Rowe Price Investment Management Inc.
2.12M $37.99M $50.89M $12.89M 33.93%
CAL
CoreCap Advisors LLC CoreCap Advisors LLC
29 $934.67 $694.84 -$239.83 -25.66%

Akoustis Technologies Inc. Analysts

Name Quantity Cost Value Profit ($) Gain (%)
AR
Alexandra Ramsey William Blair
5,341.88 $100,000 $131,917.74 $31,917.74 31.92%

Akoustis Technologies Inc. (AKTS) FAQ

What is the stock price today?

The current price is $24.21.

On which exchange is it traded?

Akoustis Technologies Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is AKTS.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 1.32B.

Has Akoustis Technologies Inc. ever had a stock split?

Akoustis Technologies Inc. had 1 splits and the recent split was on Apr 24, 2015.

Akoustis Technologies Inc. Profile

Communications Equipment Industry
Information Technology Sector
Matthew Roden CEO
NASDAQ (CM) Exchange
01021M104 CUSIP
US Country
79 Employees
- Last Dividend
24 Apr 2015 Last Split
14 Mar 2017 IPO Date

Overview

Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., designs, develops, manufactures, and sells innovative radio frequency (RF) filter products for the global mobile wireless device industry. The company operates primarily through two business segments: Foundry Fabrication Services and RF Filters. With facilities located in the United States, Asia, and Europe, Akoustis Technologies serves a worldwide customer base. Founded in 2013, the company's headquarters is in Huntersville, North Carolina. It is dedicated to providing state-of-the-art RF solutions for mobile devices, cellular infrastructure, Wi-Fi customer premise equipment, as well as military and defense applications.

Products and Services

  • Foundry Fabrication Services
  • This segment offers specialized engineering review services and backend packaging solutions to clients. It is geared towards companies looking for custom fabrication services in the RF domain, leveraging Akoustis Technologies' expertise and facilities to meet specific design and manufacturing needs.

  • RF Filters Segment
  • Under this segment, Akoustis Technologies manufactures and sells a wide range of RF filter products. These products are essential components in various applications, including:

    • Mobile Wireless Devices: The company produces RF filters that are crucial for the performance of smartphones, tablets, and other mobile wireless devices, enabling them to connect to cellular networks efficiently.
    • Cellular Infrastructure Equipment: Akoustis' filters are also used in infrastructure equipment that forms the backbone of cellular networks, ensuring reliable communication and coverage.
    • Wi-Fi Customer Premise Equipment: In addition to cellular applications, the company's filters play a key role in enhancing the performance and reliability of Wi-Fi equipment used in homes and businesses.
    • Military and Defense Applications: Akoustis Technologies also addresses the stringent requirements of military and defense applications with its high-performance RF filters, contributing to secure and reliable communication systems.

Contact Information

Address: 17 Drydock Avenue
Phone: 617-461-4023